3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia
4
Lymphoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
2
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Leukemia, T-Cell
1
Leukemia, Lymphoid
1
Burkitt Lymphoma
1
Interventions
Dexamethasone
4
nelarabine
3
Calcium Dobesilate
2
terameprocol
1
ontuxizumab
1
mogamulizumab
1
isatuximab
1
forodesine
1
fludarabine phosphate
1
fludarabine
1
crenigacestat
1
cobomarsen
1
calaspargase pegol
1
brincidofovir
1
Whole-Body Irradiation
1
Stem Cell Transplantation
1
Sirolimus
1
Sensitivity and Specificity
1
Ranitidine
1
Oxaliplatin
1
Mycophenolic Acid
1
Mesna
1
Lenalidomide
1
HBI-8000
1
Granulocyte Colony-Stimulating Factor
1
Gemcitabine
1
Filgrastim
1
Fentanyl
1
Diphenhydramine
1
Cytarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
×
forodesine
×
Clear all
NCT00742495
2012-10-24
BCX1777-108
Mundipharma Research Limited
Phase 1/2
Terminated
2 enrolled